The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 05, 2016

Filed:

Feb. 28, 2013
Applicants:

Henner Knust, Rheinfelden, DE;

Andreas Koblet, Bottmingen, CH;

Matthias Nettekoven, Grenzach-Wyhlen, DE;

Hasane Ratni, Habsheim, FR;

Claus Riemer, Freiburg, DE;

Walter Vifian, Gelterkinden, CH;

Inventors:

Henner Knust, Rheinfelden, DE;

Andreas Koblet, Bottmingen, CH;

Matthias Nettekoven, Grenzach-Wyhlen, DE;

Hasane Ratni, Habsheim, FR;

Claus Riemer, Freiburg, DE;

Walter Vifian, Gelterkinden, CH;

Assignee:

HOFFMANN-LA ROCHE INC., Nutley, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); C07D 401/06 (2006.01); A61K 31/40 (2006.01); C07D 207/14 (2006.01); C07D 403/06 (2006.01); C07D 405/06 (2006.01); C07D 407/04 (2006.01); C07D 413/06 (2006.01); C07D 417/14 (2006.01); A61K 31/4025 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/40 (2013.01); A61K 31/4025 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); C07D 207/14 (2013.01); C07D 401/06 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 407/04 (2013.01); C07D 413/06 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to compounds of formula wherein R, R, R, R, Z, and n are as defined hereinor to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).


Find Patent Forward Citations

Loading…